Global Pharma Contract Manufacturing Organisations (Cmos) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Pharma Contract Manufacturing Organisations (Cmos) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Contract manufacturing organization (CMO) is mainly to accept the commission of pharmaceutical companies to provide process development, formulation development, clinical trial drugs, chemical or biosynthetic API production, preparation production (such as powders, injections) and packaging required for product production and other services. Pharma Contract Manufacturing Organizations (Cmos) for Injectable Drug refers to a subcategory of CMO services that provides services for Injectable Drug.

Market Overview:

The latest research study on the global Pharma Contract Manufacturing Organisations (Cmos) market finds that the global Pharma Contract Manufacturing Organisations (Cmos) market reached a value of USD 38928.31 million in 2022. It’s expected that the market will achieve USD 79467.61 million by 2028, exhibiting a CAGR of 12.63% during the forecast period.

Influence of COVID-19 Outbreak on Pharma Contract Manufacturing Organisations (Cmos) for Injectable Drug Industry Development

Overall, the impact of the COVID-19 epidemic on the industry has more advantages than disadvantages.
The outbreak of COVID-19 has inevitably affected the industry chain. The epidemic has affected all aspects of the pharmaceutical and biopharmaceutical industries, from drug development, clinical trials, supply, manufacturing to supply chain logistics. Due to limited inventory of raw materials, trade and logistics restrictions, CMO services will be difficult to operate normally.
However, because drugs are an important tool for epidemic prevention and control, the overall demand for CMO services is rising. Taking WuXi AppTec as an example, the company's CDMO/CMO services will increase by 25.83% year-on-year in the first half of 2020. In 2020, the CMIC Group established a new subsidiary in Japan for process development and GMP production of antibody drugs using mammalian cell lines.

Market Driver Analysis

Pharmaceutical production requires the use of advanced technology and strict compliance with regulations, such as good manufacturing practices. After drugs are approved by regulatory authorities, pharmaceutical companies need a large supply of products for marketing and distribution. The manufacturing requirements faced by the company are huge challenges. As a result, contract manufacturing has gained popularity. By outsourcing such activities to the CMO, pharmaceutical companies can accelerate R&D activities but still generate potential revenue. Because the use of contract manufacturing and outsourcing can help large pharmaceutical companies save a lot of resources and save capital investment that would otherwise be needed for facilities and equipment.
The continuous increase of the global aging population, the continuous increase in the incidence of chronic diseases, and the substantial increase in the demand for clinical injection drugs are the main driving forces that promote the rapid development of the global injection drug market. At the same time, with the development of emerging markets, China and India have huge injection drug markets. The rapid growth of international demand for injectable drugs has promoted the demand for pharmaceutical contract manufacturing organizations in the injectable drug industry.

Region Overview:

Asia Pacific had the highest growth rate of all regions.

Company Overview:

Lonza AG is one of the major players operating in the Pharma Contract Manufacturing Organisations (Cmos) market, holding a share of 3.72% in 2020.

Lonza AG produces organic fine chemicals, biocides, active ingredients, and biotechnology products. The Company offers custom chemical manufacturing and fermentation processing and manufactures its products for the life sciences, pharmaceuticals, food processing, and agricultural products industries.

Patheon Inc. provides operates as a pharmaceutical company. The Company manufactures and develops active pharmaceutical ingredients, drugs, oral solid dose, gels, sterile, and other solutions. Patheon serves customers worldwide.

Segmentation Overview:

Among different product types, Immunoglobulin segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Pharma Company segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Pharma Contract Manufacturing Organisations (Cmos) market covered in Chapter 3:

Porton
Lonza AG
AbbVie Inc
Patheon
Catalent
Boehringer Ingelheim
Nectar Lifesciences
WuXi AppTec
Grifols International, S.A
Asymchem
Vetter
Aenova Group
CMIC Group
Recipharm
Almac Group
PCI

In Chapter 4 and Chapter 14.2, on the basis of types, the Pharma Contract Manufacturing Organisations (Cmos) market from 2018 to 2029 is primarily split into:

Blood Factors
Cytokines
Peptide Hormone
Immunoglobulin
Insulin
Other Drug Classes

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Pharma Contract Manufacturing Organisations (Cmos) market from 2018 to 2029 covers:

Pharma Company
Biotech Company

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)